Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial

Bibliographic Details
Title: Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial
Authors: Sergio España-Cueto, Cora Loste, Gemma Lladós, Cristina López, José Ramón Santos, Gemma Dulsat, Anna García, João Carmezim, Julia Carabia, Águeda Ancochea, Carla Fernández-Prendres, Cristian Morales-Indiano, Bibiana Quirant, Eva Martínez-Cáceres, Anna Sanchez, Ivonne Graciela Parraga, Anna Chamorro, Alba San José, Elena Abad, Jose A. Muñoz-Moreno, Anna Prats, Carmina R. Fumaz, Roser Coll-Fernández, Carla Estany, Pamela Torrano, Jordi Puig, Bonaventura Clotet, Cristian Tebé, Marta Massanella, Roger Paredes, Lourdes Mateu
Source: Nature Communications, Vol 16, Iss 1, Pp 1-10 (2025)
Publisher Information: Nature Portfolio, 2025.
Publication Year: 2025
Collection: LCC:Science
Subject Terms: Science
More Details: Abstract The post-COVID-19 condition (PCC) is a highly debilitating and persistent postinfectious syndrome that affects millions of people worldwide and has no effective treatment. Therapeutic plasma exchange (TPE) has the potential to improve the PCC by clearing the peripheral soluble pro-inflammatory immune milieu derived from acute or persistent SARS-CoV-2 infection. In a phase II, double-blind, placebo-controlled, randomized trial, fifty subjects with PCC were randomly assigned (1:1) to receive six sessions of either TPE or a sham plasma exchange and were followed for 90 days (ClinicalTrials.gov registration: NCT05445674). The primary endpoint was safety; secondary endpoints included functional status, symptomology, quality of life, neurocognitive symptoms, and peripheral biochemistry, hematology, coagulation and inflammation parameters. Both study arms had a similarly favorable safety profile. There were no diferences between groups in any of the efficacy parameters evaluated. Whereas TPE is safe, it did not lead to any discernible improvement of the PCC in this clinical trial.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2041-1723
Relation: https://doaj.org/toc/2041-1723
DOI: 10.1038/s41467-025-57198-7
Access URL: https://doaj.org/article/56b6107880d744a4bd9718ebbc443ad7
Accession Number: edsdoj.56b6107880d744a4bd9718ebbc443ad7
Database: Directory of Open Access Journals
More Details
ISSN:20411723
DOI:10.1038/s41467-025-57198-7
Published in:Nature Communications
Language:English